Avita Medical announces two presentations at SRBC on RECELL System

AVITA Medical (RCEL) announced two podium presentations at the 2025 Southern Region Burn Conference, SRBC, that collectively underscore the clinical and economic value of the RECELL System and reinforce its role as a standard of care for acute wound treatment. The presentations demonstrate the consistent benefits of Skin Cell Suspension Autograft prepared using the RECELL System. The findings highlight significant reductions in donor site burden, faster healing, improved patient recovery, and shorter hospital stays. Global Peer-Reviewed Evidence Establishes RECELL as a Standard of Care – The analysis of 99 peer-reviewed studies involving more than 8,000 patients across 13 countries found that RECELL: Universally reduces donor site size and burden; Achieves rapid and reliable wound closure, meeting or exceeding outcomes observed with traditional split-thickness skin grafts; Demonstrates comparable or improved pain and aesthetic outcomes; Results show favorable health economics across diverse wound types. Real-World U.S. Registry Data Show 36% Shorter Hospital Stay – Among a matched cohort, including 741 adult patients with second-degree burns less than30% total body surface area (TBSA), compared to STSG, RECELL treatment resulted in: 36% average shorter hospital stays, with significant reductions observed within each TBSA decile; 83% of patients discharged home versus 70% for STSG; Estimated cost savings of over $42,000 per patient, enabling hospitals to treat 13 additional patients per bed annually